Floatz logo

Therapeutic Asset Ratings

470 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Lubiprostone
Peritoneum Cancer
Sun Yat-sen UniversityP2CCC (53)
Penpulimab
Classic Hodgkin Lymphoma
Sun Yat-sen UniversityP2CCC (53)
Pralsetinib, trans-
Lung Cancer
Sun Yat-sen UniversityP2CCC (53)
Pralsetinib, trans-
Mutation
Sun Yat-sen UniversityP2CCC (53)
PREDNISONE TABLETS
CD5 Positive
Sun Yat-sen UniversityP2CCC (53)
PROPRANOLOL
Colon Carcinoma
Sun Yat-sen UniversityP2CCC (53)
PROPRANOLOL
Neoadjuvant Chemoimmunotherapy
Sun Yat-sen UniversityP2CCC (53)
Pucotenlimab
Nonpapillary Renal Cell Carcinoma
Sun Yat-sen UniversityP2CCC (53)
Pucotenlimab
CNLC IIIA Stage
Sun Yat-sen UniversityP2CCC (53)
Pucotenlimab
Liver Cancer
Sun Yat-sen UniversityP2CCC (53)
Pucotenlimab
Macrovascular Invasion
Sun Yat-sen UniversityP2CCC (53)
Pucotenlimab
Vorolanib
Sun Yat-sen UniversityP2CCC (53)
Pyrotinib
Concurrent Chemoradiotherapy
Sun Yat-sen UniversityP2CCC (53)
Pyrotinib
Consolidation Therapy
Sun Yat-sen UniversityP2CCC (53)
Pyrotinib
Lung Cancer
Sun Yat-sen UniversityP2CCC (53)
Pyrotinib
Mutation
Sun Yat-sen UniversityP2CCC (53)
Pyrotinib
Surufatinib
Sun Yat-sen UniversityP2CCC (53)
rc48
Disitamab Vedotin
Sun Yat-sen UniversityP2CCC (53)
rc48
ERBB2 Mutation-Related Tumors
Sun Yat-sen UniversityP2CCC (53)
rc48
RC48
Sun Yat-sen UniversityP2CCC (53)
rc48-adc
Concurrent Chemoradiotherapy
Sun Yat-sen UniversityP2CCC (53)
rc48-adc
Consolidation Therapy
Sun Yat-sen UniversityP2CCC (53)
rc48-adc
Surufatinib
Sun Yat-sen UniversityP2CCC (53)
Regorafenib
Marinesco-Sjogren Syndrome
Sun Yat-sen UniversityP2CCC (53)
Sapropterin Dihydrochloride
Pancreatic Adenocarcinoma
Sun Yat-sen UniversityP2CCC (53)
Showing 226 to 250 of 470 assets
PreviousPage 10 of 19Next